These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24991341)

  • 1. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.
    Powers A; Faria C; Broder MS; Chang E; Cherepanov D
    Am Health Drug Benefits; 2012 Nov; 5(7):455-65. PubMed ID: 24991341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
    Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
    J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
    [No Abstract]   [Full Text] [Related]  

  • 4. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia.
    Gore M; Sadosky A; Zlateva G; Clauw D
    Am J Manag Care; 2010 May; 16(5 Suppl):S144-53. PubMed ID: 20586523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States.
    Villa KF; Reaven NL; Funk SE; McGaughey K; Black J
    Am Health Drug Benefits; 2018 May; 11(3):137-145. PubMed ID: 29910845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
    Bonafede M; Anaissie E; Evans K; Itzler R
    BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
    Bell JA; Galaznik A; Blazer M; Shih HC; Farrelly E; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV
    Pharmacoecon Open; 2019 Jun; 3(2):237-245. PubMed ID: 30324565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study.
    Ueno R; Nishimura S; Fujimoto G; Ainiwaer D
    Curr Med Res Opin; 2021 Jul; 37(7):1121-1134. PubMed ID: 33989102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
    Jouzier C; Cherait A; Cony-Makhoul P; Hamel JF; Veloso M; Thepot S; Cluzeau T; Stamatoullas A; Garnier A; Guerci-Bresler A; Dimicoli-Salazar S; Pica GM; Cheze S; Santana C; Chermat F; Fenaux P; Park S
    Transfusion; 2022 May; 62(5):961-973. PubMed ID: 35452143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.